LifeStance Patients With Treatment-Resistant Depression See Clinically Meaningful Improvement in Symptoms After Esketamine or TMS Treatment, New Data Shows

LifeStance Expands Specialty Services, Increasing Access to Esketamine (Spravato) and Transcranial Magnetic Stimulation (TMS) Across the U.S. SCOTTSDALE, Ariz., Oct. 29, 2026 /PRNewswire/ -- LifeStance Health, one of the nation's largest providers of outpatient mental healthcare, is expanding access to two specialty services for treatment-resistant depression – esketamine1 (Spravato) and transcranial magnetic stimulation2 (TMS) – as separate analyses show meaningful reductions in depression symptoms and suicidal ideation among patients receiving each treatment.

PRNewsWire • 11 hours ago

LifeStance to Host Third Quarter 2026 Earnings Conference Call on November 5, 2026

SCOTTSDALE, Ariz., Oct. 15, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation's largest providers of outpatient mental healthcare, will issue its third quarter 2026 earnings release before the market opens on Thursday, November 5, 2026.

GlobeNewsWire • Oct 15, 2026

Take the Zacks Approach to Beat the Markets: HF Sinclair, Accenture & FirstCash in Focus

HF Sinclair, Accenture and FirstCash post impressive gains as Zacks research portfolios highlight standout performers amid market uncertainty and shifting investor sentiment.

Zacks Investment Research • Oct 12, 2026

Nearly Half of Americans Say Fear of an Unwanted Viral Moment Keeps Them from Being Themselves in Public, LifeStance Survey Finds

Nearly 3 in 4 Gen Zers Say Fear of an Unwanted Viral Moment Affects Their Mental Health, Self-Expression and Social Participation SCOTTSDALE, Ariz., Sept. 30, 2026 /PRNewswire/ -- A LifeStance Health survey released today finds that the possibility of spontaneous, authentic moments going viral on social media is affecting people's mental well-being and reshaping behavior, self-expression and participation in everyday life.

PRNewsWire • Sep 30, 2026

LifeStance Health CTO Sells 42,067 Shares for $541,402

Vukasin Paunovich disposed of 42,067 shares. The transaction involved shares equal to 17% of the total stake held by the executive prior to the filing.

The Motley Fool • Sep 23, 2026

LifeStance Health Group, Inc. (LFST) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

LifeStance Health Group, Inc. (LFST) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha • Sep 15, 2026

Here's Why LifeStance Health Group (LFST) is a Great Momentum Stock to Buy

Does LifeStance Health Group (LFST) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research • Sep 10, 2026

5 Low-Leverage Stocks to Buy Amid Rising Oil Prices & Inflation Woes

Rising oil prices and inflation worries shift the spotlight to five low-leverage stocks, with strong earnings growth & balance sheets.

Zacks Investment Research • Sep 10, 2026

LifeStance Health Group Announces Launch of Secondary Public Offering

SCOTTSDALE, Ariz., Sept. 09, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (“LifeStance” or the “Company”) (Nasdaq: LFST), one of the nation's largest providers of virtual and in-person outpatient mental health care, today announced that pursuant to a shelf registration statement filed with the Securities and Exchange Commission (the “SEC”), certain stockholders of the Company (the “Selling Stockholders”) intend to offer 22,250,000 shares of LifeStance's common stock, par value $0.01 per share (the “Common Stock”).

GlobeNewsWire • Sep 9, 2026

LifeStance Health Group Announces Pricing of Secondary Public Offering

SCOTTSDALE, Ariz., Sept. 09, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (“LifeStance” or the “Company”) (Nasdaq: LFST), one of the nation's largest providers of virtual and in-person outpatient mental health care, today announced the pricing of a secondary underwritten public offering of 22,250,000 shares of LifeStance's common stock, par value $0.01 per share (the “Common Stock”) at a public offering price of $12.35 per share, pursuant to a shelf registration statement filed with the Securities and Exchange Commission (the “SEC”) from certain stockholders of the Company (the “Selling Stockholders”). The Selling Stockholders will receive all of the proceeds from the offering. The Company is not selling any shares of Common Stock in the offering and will not receive any proceeds from the offering.

GlobeNewsWire • Sep 9, 2026